|
FY2024
12 months to Dec 31, 2025
|
FY2023
12 months to Dec 31, 2024
|
FY2022
12 months to Dec 31, 2023
|
FY2021
12 months to Dec 31, 2022
|
FY2020
3 months to Jun 30, 2022
|
|
|---|---|---|---|---|---|
| OPERATING REVENUE | |||||
| Capitated Revenue | |||||
| Other patient service revenue | |||||
| TOTAL OPERATING REVENUE | |||||
| OPERATING EXPENSE: | |||||
| Medical expense | |||||
| Premium deficiency reserve | |||||
| Corporate, general and administrative expense | |||||
| Sales and marketing expense | |||||
| Amortization of Intangible Assets | |||||
| Depreciation and amortization | |||||
| Goodwill impairment | |||||
| Impairment of assets held for sale | |||||
| TOTAL OPERATING EXPENSE | |||||
| OPERATING LOSS | |||||
| OTHER INCOME (EXPENSE): | |||||
| Interest expense, net | |||||
| Mark-to-market of stock warrants | |||||
| Other | |||||
| TOTAL OTHER INCOME (EXPENSE) | |||||
| Gain (Loss) on Disposition of Assets | |||||
| LOSS BEFORE INCOME TAXES | |||||
| INCOME TAX PROVISION | |||||
| NET LOSS | |||||
| LESS: NET LOSS ATTRIBUTABLE TO REDEEMABLE NON-CONTROLLING INTEREST | |||||
| NET LOSS ATTRIBUTABLE TO CONTROLLING INTEREST | |||||
| NET LOSS PER SHARE (Note 17): | |||||
| Basic (in dollars per share) | |||||
| Diluted (in dollars per share) | |||||
| WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (Note 17): | |||||
| Basic (in shares) | |||||
| Diluted (in shares) |
Loading...